{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T08:02:51Z","timestamp":1793865771606,"version":"4.6.1"},"reference-count":62,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100007632","name":"Changhua Christian Hospital","doi-asserted-by":"publisher","award":["113-CCH-IRP-007 and 112-CCH-IRP-033"],"award-info":[{"award-number":["113-CCH-IRP-007 and 112-CCH-IRP-033"]}],"id":[{"id":"10.13039\/501100007632","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Aims<\/jats:title>\n                  <jats:p>Approximately 40% of patients with steroid-refractory acute severe ulcerative colitis [SR ASUC] require colectomies. Advanced therapies may reduce the short-term colectomy rates in patients with SR ASUC. However, comparative clinical studies evaluating the effectiveness of these rescue therapies are lacking. Therefore, we conducted a network meta-analysis to study the effectiveness of rescue therapies for SR ASUC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Six randomised, controlled trials and 15 cohort studies, including 2004 patients, were analysed. Rescue drugs included tofacitinib, infliximab with a 5 or 10 mg\/kg induction dose at 0, 2, and 6 weeks [IFX and IFX10, respectively], IFX with an accelerated regimen of three 5-mg\/kg induction doses timed according to clinical need [accelerated IFX], tacrolimus, ciclosporin [CyA], ustekinumab, and adalimumab. Treatments were compared with a placebo.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Tofacitinib odds ratio [OR]: 0.09 (95% confidence interval [CI]: 0.02\u20130.52]), accelerated IFX (OR: 0.16 [95% CI: 0.03\u20130.94]), IFX (OR: 0.2 [95% CI: 0.07\u20130.58]), and tacrolimus (OR: 0.24 [95% CI: 0.06\u20130.96]) significantly reduced the short-term colectomy rates compared with placebo. IFX10 and CyA tended to prevent colectomies. However, ustekinumab and adalimumab did not significantly affect the colectomy rates.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This is the first network meta-analysis to investigate the efficacy of advanced therapies in reducing short-term colectomy rates in patients with SR ASUC. Tofacitinib, accelerated IFX, standard IFX, and tacrolimus significantly reduced the colectomy rates in SR ASUC patients compared with placebo. Thus, advanced therapies should be considered for rescue therapies in patients with SR ASUC.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjae111","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T16:24:05Z","timestamp":1720542245000},"page":"2063-2075","source":"Crossref","is-referenced-by-count":20,"title":["Rescue Therapies for Steroid-refractory Acute Severe Ulcerative Colitis: A Systematic Review and Network Meta-analysis"],"prefix":"10.1093","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6672-1332","authenticated-orcid":false,"given":"Chih-Wen","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University , Taichung ,","place":["Taiwan"]},{"name":"Division of Gastroenterology, Changhua Christian Hospital , Changhua ,","place":["Taiwan"]},{"name":"Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University , Taipei ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3494-2245","authenticated-orcid":false,"given":"Hsu-Heng","family":"Yen","sequence":"additional","affiliation":[{"name":"Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University , Taichung ,","place":["Taiwan"]},{"name":"Division of Gastroenterology, Changhua Christian Hospital , Changhua ,","place":["Taiwan"]},{"name":"Artificial Intelligence Development Center, Changhua Christian Hospital , Changhua ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang-Yuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University , Taichung ,","place":["Taiwan"]},{"name":"Division of Gastroenterology, Changhua Christian Hospital , Changhua ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,9]]},"reference":[{"key":"2024121223444358800_CIT0001","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/ajg.2011.386","article-title":"Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements","volume":"107","author":"Bitton","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"2024121223444358800_CIT0002","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.crohns.2010.02.001","article-title":"The pattern and outcome of acute severe colitis","volume":"4","author":"Dinesen","year":"2010","journal-title":"J Crohns Colitis"},{"key":"2024121223444358800_CIT0003","first-page":"56","article-title":"Contemporary medical management of acute severe ulcerative colitis","volume":"25","author":"Whaley","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2024121223444358800_CIT0004","doi-asserted-by":"crossref","DOI":"10.5217\/ir.2023.00050","article-title":"Management of ulcerative colitis in Taiwan: Consensus guideline of the Taiwan Society of Inflammatory Bowel Disease, updated in\u202f2023","author":"Yen","year":"2024","journal-title":"Intest Res"},{"key":"2024121223444358800_CIT0005","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cgh.2006.09.033","article-title":"Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression","volume":"5","author":"Turner","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024121223444358800_CIT0006","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/apt.13491","article-title":"Review article: the practical management of acute severe ulcerative colitis","volume":"43","author":"Seah","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"2024121223444358800_CIT0007","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2024121223444358800_CIT0008","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s10620-018-5358-z","article-title":"High-dose infliximab rescue therapy for hospitalized acute severe ulcerative colitis does not improve colectomy-free survival","volume":"64","author":"Chao","year":"2019","journal-title":"Dig Dis Sci"},{"key":"2024121223444358800_CIT0009","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1093\/ibd\/izy383","article-title":"Systematic review and meta-analysis: optimal salvage therapy in acute severe ulcerative colitis","volume":"25","author":"Choy","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2024121223444358800_CIT0010","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/j.cgh.2021.05.038","article-title":"Tofacitinib for biologic-experienced hospitalized patients with acute severe ulcerative colitis: a retrospective case-control study","volume":"19","author":"Berinstein","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024121223444358800_CIT0011","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/ecco-jcc\/jjad036","article-title":"Tofacitinib for acute severe ulcerative colitis: a systematic review","volume":"17","author":"Steenholdt","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2024121223444358800_CIT0012","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.cgh.2022.03.008","article-title":"Efficacy of induction therapy with calcineurin inhibitors in combination with ustekinumab for acute severe ulcerative colitis","volume":"21","author":"Veyrard","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024121223444358800_CIT0013","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/ibd\/izae038","article-title":"Clinical outcomes at 8-16 weeks after upadacitinib initiation for acute severe ulcerative colitis: a case series in the United States","volume":"30","author":"Dalal","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2024121223444358800_CIT0014","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1007\/s10620-022-07439-2","article-title":"Effectiveness of tofacitinib for hospitalized patients with acute severe ulcerative colitis: Case series","volume":"67","author":"Xiao","year":"2022","journal-title":"Dig Dis Sci"},{"key":"2024121223444358800_CIT0015","first-page":"e45416","article-title":"Tofacitinib in steroid-refractory acute severe ulcerative colitis: a retrospective analysis","volume":"15","author":"Malakar","year":"2023","journal-title":"Cureus"},{"key":"2024121223444358800_CIT0016","first-page":"923","article-title":"Emerging treatments for ulcerative colitis: a systematic review","volume":"52","author":"Kokkinidis","year":"2017","journal-title":"Scand J Gastroenterol"},{"key":"2024121223444358800_CIT0017","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"2024121223444358800_CIT0018","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/ueg2.12442","article-title":"Review article: Updated management of acute severe ulcerative colitis: from steroids to novel medical strategies","volume":"11","author":"Calm\u00e9jane","year":"2023","journal-title":"United European Gastroenterol J"},{"key":"2024121223444358800_CIT0019","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/jgh.13674","article-title":"Pharmacologic therapies for severe steroid refractory hospitalized ulcerative colitis: a network meta-analysis","volume":"32","author":"Komaki","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"key":"2024121223444358800_CIT0020","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/ajg.2016.7","article-title":"Systematic review and meta-analysis: infliximab or cyclosporine as rescue therapy in patients with severe ulcerative colitis refractory to steroids","volume":"111","author":"Narula","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"2024121223444358800_CIT0021","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3389\/fmed.2019.00338","article-title":"Comparable long-term outcomes of cyclosporine and infliximab in patients with steroid-refractory acute severe ulcerative colitis: a meta-analysis","volume":"6","author":"Szemes","year":"2019","journal-title":"Front Med [Lausanne]"},{"key":"2024121223444358800_CIT0022","article-title":"Undertaking network meta-analyses","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions, version 64","author":"Chaimani","year":"2023"},{"key":"2024121223444358800_CIT0023","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"Rob 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2024121223444358800_CIT0024","doi-asserted-by":"crossref","first-page":"3162595","DOI":"10.1155\/2016\/3162595","article-title":"A comparison of short- and long-term therapeutic outcomes of infliximab- versus tacrolimus-based strategies for steroid-refractory ulcerative colitis","volume":"2016","author":"Endo","year":"2016","journal-title":"Gastroenterol Res Pract"},{"key":"2024121223444358800_CIT0025","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1097\/MIB.0000000000000101","article-title":"Long-term comparative efficacy of cyclosporine- or infliximab-based strategies for the management of steroid-refractory ulcerative colitis attacks","volume":"20","author":"Naves","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"2024121223444358800_CIT0026","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/apt.12375","article-title":"Outcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: Ciclosporin vs. Infliximab","volume":"38","author":"Croft","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"2024121223444358800_CIT0027","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00054725-200105000-00001","article-title":"Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study","volume":"7","author":"Sands","year":"2001","journal-title":"Inflamm Bowel Dis"},{"key":"2024121223444358800_CIT0028","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.cgh.2014.07.041","article-title":"An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis","volume":"13","author":"Gibson","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024121223444358800_CIT0029","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(12)61084-8","article-title":"Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial","volume":"380","author":"Laharie","year":"2012","journal-title":"Lancet"},{"key":"2024121223444358800_CIT0030","first-page":"601","article-title":"Infliximab versus cyclosporine treatment for severe corticosteroid-refractory ulcerative colitis: a Korean, retrospective, single center study","volume":"9","author":"Kim","year":"2015","journal-title":"Gut Liver"},{"key":"2024121223444358800_CIT0031","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1111\/jgh.15508","article-title":"Comparison of outcomes of cyclosporine a and infliximab for steroid-refractory acute severe ulcerative colitis","volume":"36","author":"Song","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"2024121223444358800_CIT0032","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.crohns.2011.11.021","article-title":"Cyclosporine or infliximab as rescue therapy in severe refractory ulcerative colitis: early and long-term data from a retrospective observational study","volume":"6","author":"Mocciaro","year":"2012","journal-title":"J Crohns Colitis"},{"key":"2024121223444358800_CIT0033","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/apt.17938","article-title":"Effectiveness and safety of a third-line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin [REASUC study]","volume":"59","author":"Garc\u00eda","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"2024121223444358800_CIT0034","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s10620-020-06177-7","article-title":"Hypoalbuminemia and bandemia predict failure of infliximab rescue therapy in acute severe ulcerative colitis","volume":"66","author":"Syal","year":"2021","journal-title":"Dig Dis Sci"},{"key":"2024121223444358800_CIT0035","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1053\/j.gastro.2005.03.003","article-title":"Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study","volume":"128","author":"J\u00e4rnerot","year":"2005","journal-title":"Gastroenterology"},{"key":"2024121223444358800_CIT0036","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/ibd.21853","article-title":"Double-blind, placebo-controlled trial of oral tacrolimus [fk506] in the management of hospitalized patients with steroid-refractory ulcerative colitis","volume":"18","author":"Ogata","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"2024121223444358800_CIT0037","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1038\/ajg.2017.180","article-title":"Long-term efficacy and safety of cyclosporine in a cohort of steroid-refractory acute severe ulcerative colitis patients from the ENEIDA registry [1989-2013]: a nationwide multicenter study","volume":"112","author":"Ord\u00e1s","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"2024121223444358800_CIT0038","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2468-1253(16)30003-6","article-title":"Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis [construct]: a mixed methods, open-label, pragmatic randomised trial","volume":"1","author":"Williams","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024121223444358800_CIT0039","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1440-1746.2011.06958.x","article-title":"Infliximab or cyclosporine for acute severe ulcerative colitis: a retrospective analysis","volume":"27","author":"Dean","year":"2012","journal-title":"J Gastroenterol Hepatol"},{"key":"2024121223444358800_CIT0040","first-page":"370","article-title":"Infliximab is more effective than cyclosporine as a rescue therapy for acute severe ulcerative colitis: a retrospective single-center study","volume":"34","author":"Grazie","year":"2021","journal-title":"Ann Gastroenterol"},{"key":"2024121223444358800_CIT0041","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1111\/jgh.14072","article-title":"Predicting response after infliximab salvage in acute severe ulcerative colitis","volume":"33","author":"Choy","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"2024121223444358800_CIT0042","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1056\/NEJM199406303302601","article-title":"Cyclosporine in severe ulcerative colitis refractory to steroid therapy","volume":"330","author":"Lichtiger","year":"1994","journal-title":"N Engl J Med"},{"key":"2024121223444358800_CIT0043","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/apt.13531","article-title":"Tacrolimus vs. Anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: a retrospective observational study","volume":"43","author":"Yamamoto","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"2024121223444358800_CIT0044","doi-asserted-by":"crossref","first-page":"S","DOI":"10.1016\/S0016-5085(12)60768-9","article-title":"1125 oral tacrolimus versus cyclosporine a in patients with moderate to severe ulcerative colitis refractory to corticosteroids","volume":"142","author":"Aoki","year":"2012","journal-title":"Gastroenterology"},{"key":"2024121223444358800_CIT0045","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/S1873-9946(09)60154-9","article-title":"P127 - oral cyclosporin vs infliximab in patients with severe ulcerative colitis refractory to iv steroids. Preliminary data of a controlled, randomized study","volume":"3","author":"Bossa","year":"2009","journal-title":"J Crohns Colitis"},{"key":"2024121223444358800_CIT0046","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/gut.2005.081794","article-title":"A randomised dose finding study of oral tacrolimus [fk506] therapy in refractory ulcerative colitis","volume":"55","author":"Ogata","year":"2006","journal-title":"Gut"},{"key":"2024121223444358800_CIT0047","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.14309\/ajg.0000000000002635","article-title":"Tofacitinib in acute severe ulcerative colitis [TACOS]: a randomized controlled trial","volume":"119","author":"Singh","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"2024121223444358800_CIT0048","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1097\/MPG.0000000000003616","article-title":"Tofacitinib salvage therapy for children hospitalized for corticosteroid- and biologic-refractory ulcerative colitis","volume":"75","author":"Constant","year":"2022","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2024121223444358800_CIT0049","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/apt.16463","article-title":"Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: a GETAID cohort","volume":"54","author":"Uzzan","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2024121223444358800_CIT0050","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/ecco-jcc\/jjaa018","article-title":"Tofacitinib for rescue therapy in acute severe ulcerative colitis: a real-world experience","volume":"14","author":"Kotwani","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2024121223444358800_CIT0051","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.dld.2023.05.021","article-title":"The current role of tofacitinib in acute severe ulcerative colitis in adult patients: a systematic review","volume":"55","author":"Mpakogiannis","year":"2023","journal-title":"Dig Liver Dis"},{"key":"2024121223444358800_CIT0052","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"2024121223444358800_CIT0053","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00535-018-1439-1","article-title":"Evidence-based clinical practice guidelines for inflammatory bowel disease","volume":"53","author":"Matsuoka","year":"2018","journal-title":"J Gastroenterol"},{"key":"2024121223444358800_CIT0054","doi-asserted-by":"crossref","first-page":"e00642","DOI":"10.14309\/ctg.0000000000000642","article-title":"Comparative effectiveness of tacrolimus and infliximab in hospitalized patients with ulcerative colitis","volume":"15","author":"Takahashi","year":"2024","journal-title":"Clin Transl Gastroenterol"},{"key":"2024121223444358800_CIT0055","doi-asserted-by":"crossref","first-page":"700","DOI":"10.3109\/00365521.2016.1138239","article-title":"Comparison of the therapeutic efficacy and safety between tacrolimus and infliximab for moderate-to-severe ulcerative colitis: a single center experience","volume":"51","author":"Nuki","year":"2016","journal-title":"Scand J Gastroenterol"},{"key":"2024121223444358800_CIT0056","first-page":"151","article-title":"A comparison of short-term therapeutic efficacy between infliximab and tacrolimus for moderate to severe ulcerative colitis","volume":"55","author":"Yamagami","year":"2017","journal-title":"Rom J Intern Med"},{"key":"2024121223444358800_CIT0057","doi-asserted-by":"crossref","first-page":"e22894","DOI":"10.1097\/MD.0000000000022894","article-title":"Efficacy of infliximab, cyclosporine and tacrolimus on ulcerative colitis: a meta-analysis","volume":"99","author":"Jia","year":"2020","journal-title":"Medicine [Baltim]"},{"key":"2024121223444358800_CIT0058","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1007\/s10620-019-05957-0","article-title":"Use of accelerated induction strategy of infliximab for ulcerative colitis in hospitalized patients at a tertiary care center","volume":"65","author":"Govani","year":"2020","journal-title":"Dig Dis Sci"},{"key":"2024121223444358800_CIT0059","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.cgh.2018.06.031","article-title":"Effect of accelerated infliximab induction on short- and long-term outcomes of acute severe ulcerative colitis: a retrospective multicenter study and meta-analysis","volume":"17","author":"Nalagatla","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024121223444358800_CIT0060","first-page":"49","article-title":"A practical marker to determining acute severe ulcerative colitis: CRP\/albumin ratio","volume":"7","author":"Sayar","year":"2020","journal-title":"North Clin Istanb"},{"key":"2024121223444358800_CIT0061","doi-asserted-by":"crossref","first-page":"i1611","DOI":"10.1093\/ecco-jcc\/jjad212.1002","article-title":"P872 PREDICT UC: Optimising infliximab induction therapy for acute severe ulcerative colitis: a randomised controlled trial","volume":"18","author":"Choy","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2024121223444358800_CIT0062","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/aid2.13300","article-title":"Real-world experience of adalimumab therapy for patients with ulcerative colitis: a single tertiary medical center experience in central Taiwan","volume":"10","author":"Yen","year":"2023","journal-title":"Adv Dig Med"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjae111\/58719792\/jjae111.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/18\/12\/2063\/60911843\/jjae111.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/18\/12\/2063\/60911843\/jjae111.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T23:45:03Z","timestamp":1734047103000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/18\/12\/2063\/7709964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":62,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,7,9]]},"published-print":{"date-parts":[[2024,12,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae111","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,7,9]]}}}